Showing promise in the landscape of excess body fat therapy, retatrutide represents a different approach. Unlike many available medications, retatrutide works as a double agonist, concurrently affecting both GLP peptide-1 (GLP-1) and glucose-sensitive insulinotropic hormone (GIP) binding sites. This simultaneous engagement encourages multiple benef